PDCD1 and Autoimmunity: Nevertheless, a significant minority of patients on PD-1 blockade develop immune-related adverse events (irAEs)—i.e., autoimmunity—including neurological, intestinal, pulmonary, hepatic and renal disease, and endocrinopathy (Martins et al., 2019).